Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Robinson, Karen A ^a   Odelola, Olaide A ^b   Saldanha, Ian J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

CHILD; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE; MORTALITY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; WEIGHT GAIN; COMPLICATION; DRUG ADMINISTRATION; INFANT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANTIVIRAL AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; PALIVIZUMAB; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84978646673     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007743.pub6     Document Type: Review

References (54)

1. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Poster session presented at the American Thoracic Society International Conference 2005 May 20-25; San Diego, USA. 2005.
2. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of Synagis® (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract]. Proceedings of the American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005:A178.
3. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124(6):1694-701. [DOI: 10.1542/peds.2009-2345]
4. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis. Journal of Pediatrics 1988;113(5):826-30.
5. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatric Pulmonology 1998;26(6):371-9.
6. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV Database. Pediatric Investigators Collaborative Network on Infections in Canada. The Pediatric Infectious Disease Journal 1999;18(10):866-9.
7. Cane PA. Molecular epidemiology of Respiratory Syncytial Virus. Reviews in medical virology 2001;11(2):103-16.
8. Cystic Fibrosis Foundation. Newborn screening for cystic fibrosis. http://www.cff.org/GetInvolved/Advocate/NewbornScreening (accessed December 03, 2009).
9. Colasurdo GN, Fullmer JJ, Elidemir O, Atkins C, Khan AM, Stark JM. Respiratory syncytial virus infection in a murine model of cystic fibrosis. Journal of Medical Virology 2006;78(5):651-8.
10. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Dupont WD, Plummer WD. Power and Sample Size Calculations: A Review and Computer Program. Controlled Clinical Trials 1990;11:116-28.
12. Efthimiou J, Hodson ME, Taylor P, Taylor AG, Batten JC. Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax 1984 Feb;39(2):150-4.
13. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003;143(4):532-40.
14. Fenton C, Scott LI, Plosker GL. Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection. Pediatric Drugs 2004;6(3):177-97.
15. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatric Pulmonology 2008;43(2):169-74.
16. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases in Children 1986;140(6):543-6.
17. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 2005 Aug;16(5):386-92.
18. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103(3):619-26.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistence in meta-analyses. BMJ 2003;327(7414):557-60.
20. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
22. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4):1075-82.
23. Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;154(5):1426-9.
24. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600.
25. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatric Infectious Disease Journal 2002;21(7):629-32.
26. McCormick J, Southern KW. A survey of palivizumab for infants with cystic fibrosis in the UK. Archives of disease in childhood 2007;92(1):87-8.
27. Mejias A, Chavez-Bueno S, Rios AM, Saavedra-Lozano J, Aten MF, Hatfield J, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrobial Agents and Chemotherapy 2004;48(5):1811-22.
28. National Health Service. Newborn Blood Spot screening across the UK . http://www.screening.nhs.uk/bloodspot-compare (accessed December 03, 2009).
29. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatric Infectious Disease Journal 2003;22(9):823-7.
30. Piedimonte G, Hegele RG, Auais A. Persistent airway inflammation after resolution of respiratory syncytial virus infection in rats. Pediatric Research 2004;55(4):657-65.
31. Pohl C, Green M, Wald ER, Ledesma-Medina J. Respiratory syncytial virus infections in pediatric liver transplant recipients. Journal of Infectious Diseases 1992;165(1):166-9.
32. Purcell K, Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatric Infectious Disease Journal 2004;23(5):418-23.
33. Physician's Desk Reference. Red Book Drug Topics. Montvale, NJ: Thomson Reuters, 2009.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
35. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. European Journal of Pediatrics 2003;162(4):237-44.
36. Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in Children: A National Clinical Guideline. www.sign.ac.uk/pdf/sign91.pdf (accessed 22 January 2009).
37. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstén B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95(4):500-5.
38. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1501-7.
39. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. American Journal of Respiratory and Critical Care Medicine 2005;171(2):137-41.
40. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. Journal of Pediatrics 2007;151(1):34-42, 42.e1.
41. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatric Infectious Disease Journal 2003;22(6):540-5.
42. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. A survey of newborn screening for cystic fibrosis in Europe. Journal of Cystic Fibrosis 2007;6(1):57-65.
43. Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. The Pediatric Infectious Disease Journal 2008;27(6):559-61.
44. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354(9178):541-5.
45. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. Journal of Biological Chemistry 2005;280(42):35751-9.
46. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289(2):179-86.
47. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Archives of Disease in Childhood 2009;94(2):99-103. [DOI: 10.1136/adc.2008.139188; PUBMED: 18653625]
48. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the pediatric population in Spain. Epidemiology and Infection 2003;131(2):867-72.
49. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. New England Journal of Medicine 1984;311(26):1653-8.
50. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001725.pub2]
51. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007743.pub2]
52. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD007743.pub3]
53. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD007743.pub4]
54. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD007743.pub5]